Home > Newsroom > Publications> News Archive

Please note: This article is part of the Cancer Center's News Archive and is here for historical purposes. The information and links may no longer be up-to-date.

Michigan Oncology Journal Fall 97

Of Interest

News

Cancer Center Dedicates Building<
“In this new facility treatment and research will be on the cutting edge, but care will be given the old fashioned way — with passion and heart,” said Gov. John Engler in his speech at the Cancer Center’s Dedication Ceremony on Friday, June 13. Other speakers included Vice Provost for Medical Affairs Emeritus George D. Zuidema, M.D., Cancer Center Director Max S. Wicha, M.D.; Geriatrics Center Director Jeffrey B. Halter, M.D.; President Lee C. Bollinger; and former U-M Athletic Director and Football Coach Glenn E. “Bo” Schembechler.

Aging the Focus of President’s Cancer Summit at U-M
With cancer mortality rates declining due to advances in research, more people are living longer. Older Americans and their care givers now must confront cancer in new ways. That issue was the focus of the latest summit meeting of the President’s Cancer Panel, “Cancer and the Aging Population,” held Thurs., July 31, 1997 at the U-M.

U-M Physicians Listed Among Best Doctors for Women
Cancer Center director of gynecologic oncology Vicki V. Baker, M.D., and gyne-oncologist George W. Morley, M.D., were listed among the best doctors for women in the August 1997 issue of Good Housekeeping. The magazine surveyed more than 200 department chairs and section chiefs in obstetrics and gynecology at major U.S. medical centers.

Clinical Trial

Phase I/II Study Evaluating the Safety and Biological Activity of Recombinant Vaccinia Prostate-Specific Antigen (Vaccinia-PSA) Vaccine in Patients with Serological Recurrence of Prostate Cancer Following Radical Prostatectomy

The purpose of this phase I/II trial is to study the effects of a PSA vaccine in men with prostate cancer that has recurred following radical prostatectomy. Patients will receive an injection of the vaccine followed by observation for two hours. Treatment may be repeated. Telephone follow-up will be on days 1, 3, and 5 after vaccine injection. Thereafter patients will have follow-up evaluations at the clinic. To be eligible, patients must have rising PSA levels, no chemotherapy, no flutamide for at least four to six weeks, no corticosteroids for at least 28 days, no metastases, no radiation therapy for at least 6 months and no radiation therapy to the head, not had the spleen removed, not had androgen ablation, no other cancer within the past five years except skin cancer, superficial bladder cancer, or in situ cancer other than of the urinary tract, received smallpox vaccine, no current or previous skin conditions, and no other serious medical problems. Patients must also have no close contact with children less than three years of age, pregnant women, or persons with skin conditions for at least two weeks after vaccination.

New Faculty

Darrell J. Fader, M.D.
Assistant Professor in the Department of Dermatology
Previously served as Lecturer, U-M Department of Dermatology
Area of Expertise: Mohs chemosurgery, dermatologic surgery and laser surgery

 

John Wei, M.D.
Lecturer in the Departments of Surgery and Medicine, Robert Wood Johnson Clinical Scholar
Previously served as chief resident in Urology, New York Hospital Cornell Medical Center
Area of Expertise: services research.

 

Return to top